Enrollment completed six months ahead of guidance, driven by significant unmet need for better treatments in CSUTopline data expected Q4 2026BLA submission planned for 2027 HAMPTON, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today the completion of enrollment in the Company’s global Phase 3 program of barzolvolimab in chronic spontaneous urticaria (CSU), which consists of two Phase 3 trials—EMBARQ-CSU1 and EMBARQ-CSU2. 1,939 patients were enrolled—the largest program conducted i ...

BOSTON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces positive new biomarker data from a late-breaking poster titled “Nasal foralumab downregulates CSF inflammation and upregulates CSF neuroprotective proteomic pathways which correlate with [F-18]PBR06-PET imaging in na-SPMS with PIRA,” which was presented by investigators from Brigha ...

Immunocore reports fourth quarter and full year 2025 financial results and provides a business update KIMMTRAK (tebentafusp-tebn) Q4 net sales of $104.5 million and $400.0 million for full year 2025; expect moderating revenue growth in 2026 TEBE-AM enrollment completion anticipated 1H 2026 with topline data expected as early as 2H 2026 PRAME franchise Phase 1/2 data to be presented in 2H 2026: brenetafusp in ovarian and lung cancer, and initial data with half-life extended candidate (IMC-P115C) Additional ...

WALTHAM, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will participate in a hybrid presentation followed by an analyst-led Q&A session at the TD Cowen 46th Annual Health Care Conference being held at the Boston Marriott Copley Place in Boston, MA on Wednesday, March 4, 20 ...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter and year ended December 31, 2025. Full year 2025 revenues rose to a record $3.18 billion, reflecting 11% growth over 2024. "As we close out another remarkable year with record total revenue for the fourth year in a row, I extend my thanks to our Unitherians whose unwavering commitment to innovation. ...

Financial Performance - ImmunityBio reported a 700% year-over-year increase in net product revenue for its lead immunotherapy, ANKTIVA, reaching $113 million [1][4] - The company experienced a net loss of $351.4 million for the year, which was a reduction from 2024 losses, attributed to significant revenue offset and lower administrative expenses [2] Sales and Market Expansion - There was a 750% increase in unit sales volume for ANKTIVA, along with a 20% sequential growth in Q4, indicating strong clinical adoption [1] - ImmunityBio established a global commercial footprint with regulatory authorizations in 33 countries, including the US, UK, EU, and Saudi Arabia [2] Product Development and Partnerships - Saudi Arabia approved ANKTIVA for a second indication, metastatic non-small cell lung cancer, marking its first validation in solid tumors beyond bladder cancer [4] - The company formed partnerships with Accord Healthcare in Europe and BioPharma & Cigalah in the Middle East, and established new subsidiaries in Dublin and Riyadh [4] Strategic Vision - ImmunityBio is advancing a three-year global strategy that positions ANKTIVA as the backbone for its Cancer BioShield platform, targeting various tumor types such as glioblastoma, pancreatic cancer, and lymphoma [4]

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE034, a Potential First-In-Class B7H3/PTK7 Bispecific TOP1 ADC [Accessibility Statement] Skip Navigation- B7H3/PTK7 co-expressed in 30-40% of multiple solid tumor types, including lung, breast, ovarian and colorectal cancers- Potential as a monotherapy and in combination with proprietary PARG inhibitor, IDE161- Phase 1 dose escalation trial to determine safety, tolerability and PK of IDE034SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 /PRNews ...

Core Viewpoint - PreveCeutical Medical Inc. has received approval for its Canadian Patent Application No. 3127020, which pertains to a cyclic peptide aimed at pain management, marking a significant milestone in the company's pain therapy program [1][3]. Patent Details - The patent application focuses on novel cyclized peptides that are analogues of dynorphin, designed to provide effective pain relief while minimizing adverse effects associated with traditional opioids [2]. - The patent is co-owned with The University of Queensland and is expected to be granted in Q2 2026, providing exclusivity in Canada until January 2040, with additional applications pending in the U.S., Europe, and Australia [3]. Technology and Development - PreveCeutical's pain therapy program aims to develop next-generation peptide-based analgesics that address the limitations of conventional opioids through advanced peptide engineering and cyclization techniques [4]. - The company is committed to pioneering safer alternatives to opioids, reinforcing its position in a market that increasingly demands such solutions [5]. Company Overview - PreveCeutical is a health sciences company focused on innovative preventive and curative therapies, with multiple research and development programs targeting various health issues, including non-addictive analgesic peptides [6].

Caris Life Sciences, Inc. (NASDAQ:CAI) is among the 11 Newly-Listed NASDAQ Stocks to Buy Now. Baird Initiates Coverage of Caris Life Sciences, Inc. (CAI) with an Outperform Rating On February 17, 2026, Baird initiated coverage of Caris Life Sciences, Inc. (NASDAQ:CAI) with an Outperform rating and a $26 price target. Baird described Caris Life Sciences, Inc. (NASDAQ:CAI) as a commercial-stage precision oncology company focused on comprehensive molecular information and machine learning algorithms. While ...

Headquartered in Washington, D.C., Danaher Corporation (DHR) is a global science and technology powerhouse focused on biotechnology, life sciences, and diagnostics. With a market capitalization of nearly $149 billion, it sits in the “large-cap” territory, a space reserved for companies valued above $10 billion. This scale gives Danaher the muscle to build bioprocessing systems, precision laboratory instruments, genomic technologies, and clinical diagnostic platforms that anchor drug development, scientif ...